Two new medications which fight drug-resistant superbugs could soon become available to NHS patients in England after the National Institute for Health and Care Excellence (NICE) said they offered value for money.
NICE said Cefiderocol and ceftazidime-avibactam will be the first antimicrobial drugs to be made available as part of a subscription-style payment model that incentivises research and development of antimicrobials by testing new approaches to evaluating and paying for them.
As part of part of a project with the NHS and the Department of Health and Social Care, the new payment model is designed to address the growing threat posed by antimicrobial resistance - a serious global problem - which develops when the pathogens that cause infection evolve to make antibiotics and other antimicrobial
drugs less effective or stop them from working altogether.
All pharmacy businesses are reporting that they are struggling to find the registered professionals needed to open their pharmacies, clarified the Company
Chemists' Association (CCA) in response to an attack by the Pharmacists' Defence Association.
Last week, PDA allegedly accused some large pharmacy chains of 'orchestrating' full or part-time closures of some of their shops due to the staff shortage.
In its Open Letter published on Tuesday (July 19), PDA demanded urgent action "to protect patients by ensuring that essential community pharmacy services are
provided safely and consistently".
"All parts of the healthcare system are struggling to recruit staff and to assume that pharmacies would be immune to such pressures, seems fanciful," said CCA.
"CCA members are working extraordinarily hard to prevent temporary closures, but recruitment and retention of pharmacists is becoming increasingly tough. The recent
rise in Covid cases and the beginning of the summer holiday season in parts of the UK have only worsened the situation."
The Association also showed data from the PSNC Pharmacy Pressures Survey (April 2022) which found that 91 per cent of pharmacies are experiencing staff shortages,
clearly demonstrating that these shortages are affecting the entire sector.
The Department of Health and Social Care (DHSC) has introduced a new 'swap to stop' scheme to encourage one million smokers to swap cigarettes for vapes in
England.
As part of the world-first national scheme, almost 1 in 5 of all smokers in England will be provided with a vape starter kit alongside behavioural support to help
them quit the habit as part of a series of new measures to help the government meet its ambition of being smokefree by 2030 - reducing smoking rates to 5% or less.
Local authorities will also be invited to take part in the scheme later this year and each will design a scheme which suits its needs, including deciding which
populations to prioritise.
Health Minister Neil O'Brien announced on Tuesday (11 April) that pregnant women will be offered financial incentives to help them stop smoking. This will involve
offering vouchers, alongside behavioural support, to all pregnant women who smoke by the end of next year.
The government will also consult on introducing mandatory cigarette pack inserts with positive messages and information to help people to quit smoking.
It has also announced a formation of new 'illicit vapes enforcement squad' to regulate and tackle the sales of illegal vapes to under 18s.
FreeStyle Libre 3 Sensors and Budesonide 500microgram orodispersible tablets sugar free have been included in the Drugs for which Discount is Not
Deducted (DND) list (Part II of the Drug Tariff) from January 2024, according to Community Pharmacy England (CPE).
Following applications made by CPE on behalf of pharmacy contractors, the Department of Health and Social Care (DHSC) agreed to give DND status to these
products to ensure that "pharmacies are not faced with dispensing these sensors at a loss."
Updated monthly by the DHSC, Part II of the Drug Tariff includes grouped and individual items.
Recently launched by Abbott Diabetes Care Ltd, FreeStyle Libre 3 Sensors have also been added to the Appliances section in Part IXA of the January 2024 Drug Tariff.
As the sensors can only be ordered by pharmacies directly from the manufacturer without any discount, CPE requested the DHSC to exempt this appliance from any
discount deduction.
Now is the best time for community pharmacy to integrate its model of NHS representation and support to ensure better outcomes for contractors, said James Wood, director of Contractor & LPC Support, Pharmaceutical Services Negotiating Committee (PSNC).
It is important for the sector to adapt to the new landscape and address challenges such as workforce, digital data, integration of pharmacy services, and medicines optimisation, he said during the first session of the sixth annual Pharmacy Business Conference held online on Tuesday, September 21.
Under the new system, every part of England will be covered by integrated care systems (ICSs) from April 2022. ICSs have been created to bring about big changes in how health and care services in England are planned, paid for and delivered. They are a key part of the direction of travel for the NHS as outlined in the NHS Long Term Plan.
Pharmacists and pharmacy technicians are set to receive up to £15.9 million over the next four years which will help them thrive in multidisciplinary healthcare teams and enable expansion of frontline staff in primary and community care.
The funding, which is part of the Pharmacy Integration Programme allocation, will improve registered pharmacy professionals' skills, through a range of training
and development opportunities.
The programme is a part of education reform for pharmacy professionals and will allow them to identify career pathways.
Health Education England and NHS England will work in partnership to develop "a formal portfolio recognition process to identify the existing skills, training and experience gained by pharmacists working in primary care, allowing them to work more flexibly and better support GP services", HEE said in a statement today (November 8).
The Pharmacists' Defence Association (PDA) has raised the issue faced by the pharmacy students on returning to in-person assessments while urging the
universities to take an empathetic approach in transition of online to in-person exams.
It was highlighted by the association that many student members were apprehensive about the return to in-person assessments. This is due to their continuing worry of Covid-19 transmissions and anxiety caused by changing exam formats and procedures.
However, with the ease of Covid restrictions, now pharmacy schools are able to decide how exams are conducted but the PDA believes that they should communicate the
process to students in advance.
"A return to normal university life is considered to be beneficial to student health and well-being. In-person exams are an important part of preparing for students' future trainee assessment examinations, GPhC accreditation for pharmacy schools, and ensuring the integrity of exam results. As future healthcare professionals, face-to-face interaction is also an integral part of the role," said the PDA.
Bas Vorsteveld, who was made vice president and general manager for Great Britain & Ireland (GBI) in November last year, is joined by Monica Michalopoulou as GBI marketing director and Onyeka Anugwom as GBI commercial excellence director GSK Consumer Healthcare.
He took over from Jonathan Workman, who held the position from 2018, and has now moved into the role of Business Unit general manager for Northern Europe.
Vorsteveld, who has 15 years' industry experience, played at major part in the merger of Novartis and GSK consumer healthcare businesses. Most recently, he held
the role of VP & head of commercial excellence EMEA LATAM at GSK Consumer Healthcare, where he spearheaded international sustainability initiatives.
Commenting on his new role, Vorsteveld said: "I am incredibly honoured to have been a part of GSK Consumer Healthcare's journey to date and it is our collective ambition to deliver better everyday health with humanity for our customers, with a laser focus on 'self-care'.
"The recent pandemic has shown us that healthcare matters more now than ever before for our consumers. We want to redefine the role that self-care plays in people's lives, because it can bring long-term benefits for individuals and society, and is a key component of a sustainable healthcare system.
The Department of Health and Social Care (DHSC) announced on Monday (November 22) that it would integrate NHS Digital, NHSX and Health Education England into NHS England and Improvement (NHSE&I) as part of major workforce planning and technology reforms.
The merger is part of the government's long-term strategy for the recruitment, training and retention of healthcare staff coupled with a digital transformation of
working practices.
The overhaul is based on recommendations made by NHS Digital chair Laura Wade-Gery who led a government-commissioned review to improve patient care, centralise the NHS workforce and accelerate digital delivery.
Commenting on her recommendations, Wade-Gery, said: "In the rest of our lives, digital has really changed how we live and we must now make this true in healthcare.
The goal of my review is to equip the national centre with the right capability to support Integrated Care Systems to deliver better citizen health. We need to have
the culture, operating model, skills, capabilities and processes to put data, digital and technology at the heart of how we transform health services."
The journey on building inclusive teams and increasing ethnic diversity and representation at all levels is never ending, said Sanjay Bhandari, chair at Kick It Out.
"I think you can set the direction but it's quite difficult to set the destination with these things," Bhandari, who is part of the government-sponsored Parker review into the ethnic diversity of UK boards said during a panel discussion on Inclusive Leadership held as part of the Pharmacy Business Diversity Conference on Thursday (December 9).
He said the aim of the review was to fix a destination like a milestone, it's not the ultimate destination.
Bhandari highlighted that "most organisations have not even started and so a good way of getting started was by the end of 2021 to have at least one British born director of colour on your board for the FTSE 100 (companies)."
The idea of the review is to "focus on that pathway and filling the hole inthedoughnut," Bhandari said.
The PDA has raised concerns over the 'deliberate breaches' of the NHS contract by some community pharmacy businesses, saying that it may cause harm to patients
and damage the reputation of the profession.
The organisation said concerned pharmacists have revealed to them that some businesses are now explicitly saying that if locums will not agree to work for less
than a so-called 'maximum' hourly rate, the business will close the pharmacy for either part of, or the whole day.
Some of these full or part-day closures are being communicated significantly in advance of the actual day, it added.
The union further alleged that several pharmacy businesses seem to have simultaneously implemented identical so-called 'maximum rates' in what could be an
anti-competitive behaviour.
To help pharmacy owner to better understand the negotiating process, Community Pharmacy England (CPE) has published commentary and infographics.
"Our work to negotiate fair funding, as well as changes to NHS pharmacy services, with the Department of Health and Social Care (DHSC) and NHS England is a
crucial part of our role," said CPE.
"Understandably the sector is eagerly awaiting an update on the progress of the current negotiations on the Government's pledge to invest £645m in community
pharmacies and, as part of our ongoing efforts to improve transparency of our work, we have released materials to explain the negotiating process."
Negotiating Team Member Stephen Thomas - who joined the team this year - has written a blog about his experiences.
He has described both the complexity of the process and volume of work undertaken, and recognises the significance of his role on behalf of pharmacy owners across
the country.
Whilst speed is of the essence, even higher on the Negotiating Team's list of priorities is working through a large number of important questions - particularly
around the funding and logistics that need to be put in place.
New data published by the UK Health Security Agency (UKHSA) has revealed that London is potentially at risk of a measles resurgence.
UKHSA modelling suggests that, unless MMR vaccination rates improve, London could see a measles outbreak with tens of thousands of cases.
"Those who have never received a measles vaccine (MMR) are at risk," said UKHSA.
MMR is part of the NHS Routine Childhood Immunisation Programme. Parents whose infants missed out, or anyone of any age unvaccinated, are urged to come forward.
Susceptibility is particularly high among 19 to 25 year olds, affected by unfounded stories in the early 2000s ('Wakefield cohorts') and some may still not be
fully vaccinated.
As part of continued efforts to protect people against getting measles, the NHS is launching a campaign encouraging people to check their vaccination status, with
targeted outreach to groups in London.
Chair of the Health and Social Care Committee Steve Brine MP has called on community pharmacy contractors to join a newly launched a parliamentary 'call for
evidence' which will look into 'prevention' as a key to the future of the NHS.
A former pharmacy minister and keen supporter of the sector, Mr Brine has called on all community pharmacists to "make their contribution count" by taking part in a
major inquiry which will remain open for submission until Wednesday 8 February 2023 and will also involve general practitioners, nurses and other health professionals.
Community pharmacists can submit their proposals written under 750 words, outlining what they think are the issues around prevention the parliamentary body should
explore, why these issues deserve the Commons Select Committee's attention, and how government policy could be developed or improved to address them.
The submissions will then be used to help the committee decide where it should focus its attention in the later stages of the inquiry on prevention, which is a vital
part of the NHS Long Term Plan.
David Webb, the Chief Pharmaceutical Officer for England, acknowledged that the "pressure in the system is high", but urged everyone to "keep our eye on the
design" of the NHS plan, adding that the "the objective is to bring the different parts of primary care together" in the patient interest.
Speaking during the opening keynote session at the the National Pharmacy Association (NPA) conference held on Thursday (13 October), he added that the NHS plan
intends to bring different parts of primary care together to help patients.
He said the new integrated care boards (ICBs) are a key strategic framework as they provide the "potential to form partnerships to deliver integrated services across
larger populations".
"ICBs will want to work with Local Pharmaceutical Committees to plan for the local population and the new community pharmacy clinical leads in ICBs, who have been
funded by NHS England, are there to advise."
He explained that once an ICB takes over the commissioning of pharmaceutical services (which they are all due to do by April 2023), it could use its funds to
commission a local enhanced service as an add on to an advanced service. For instance, a CVD risk assessment could be added to the blood pressure check service.
Lapses in strategies to tackle COVID-19 this year continue to create the perfect conditions for a deadly new variant to emerge, as parts of China witness a
rise in infections, the head of the World Health Organization said on Friday (December 2).
The comments by WHO Director-General Tedros Adhanom Ghebreyesus mark a change in tone just months after he said that the world has never been in a better position
to end the pandemic.
"We are much closer to being able to say that the emergency phase of the pandemic is over, but we're not there yet," Tedros said on Friday.
The global health agency estimates that about 90% of the world's population now has some level of immunity to SARS-COV-2 either due to prior infection or vaccination.
"Gaps in testing … and vaccination are continuing to create the perfect conditions for a new variant of concern to emerge that could cause significant mortality,"
Tedros said.
COVID-19 infections are at record highs in China and have started to rise in parts of Britain after months of decline.
The Pharmaceutical Services Negotiating Committee (PSNC) has launched Pharmacy Pressures Survey 2023 to make case against the 'unprecedented financial and
operational challenges' faced by the community pharmacies in England.
The Committee has urged those working in or owns a community pharmacy to 'take part' in the survey.
"The survey results will be critical to help us to show Government and the NHS how difficult things now are for pharmacies, and to persuade them to take action. We
will be using the results in our negotiations, in our conversations with MPs, Ministers and in national media work as part of the joint #saveourpharmacies campaign,"
said PSNC.
The Pharmacy Pressures Survey is once again comprised of two surveys to give insight into both financial and operational pressures.
Together with the other national pharmacy organisations PSNC are working both to show policy makers the severity of the problems and to lobby for Government and NHS
action to ease the pressures.
The Association of the British Pharmaceutical Industry (ABPI) on Thursday (February 2) called for the government to scrap its plans to raise the repayment rates
for drugmakers, to avoid possible setbacks in the sector.
Drugmakers that are part of the government's voluntary scheme agreement, which makes branded medicines affordable for people, are required to pay a part of their
drug revenue to the government.
The Department of Health and Social Care plans to raise the revenue clawback rate to 27.5 per cent from 24.5 per cent.
The country's ongoing attempt to raise rates is likely to send the "worst possible signal" to global investors and boardrooms, said the ABPI.
"Hiking these clawbacks to such uncompetitive levels risks undermining the UK's offer to global life sciences companies," Richard Torbett, chief executive of the
ABPI, said in a statement.
Pharmaceuticals giants AbbVie and Eli Lilly withdrew from the UK's voluntary drug pricing agreement in January after the repayment rates surged to 26.5 per cent.
The Pharmaceutical Services Negotiating Committee (PSNC) has appointed Robbie Turner as chief transformation officer, to work closely with LPCs as part of its
newly launched Transforming Pharmacy Representation (TAPR) programme.
PSNC launched the TAPR Programme in response to the contractor vote in favour of the Review Steering Group's proposals. As part of the programme - alongside
actioning the recommendations for PSNC - there will be support for LPCs to implement their proposals.
Williams will be responsible for leading, driving, and having oversight of the TAPR workstream to increase efficiency and outcomes across the network of LPCs in
England.
This will include the provision of specialist hands-on guidance and support to LPC members and officers, to promote implementation of the RSG proposals, best
practice and challenging the status quo.
Williams was formerly chief officer of Community Pharmacy West Yorkshire LPC and subsequently Director for England and Director of Pharmacy and Member Experience
at the Royal Pharmaceutical Society.
The Pharmaceutical Defence Association (PDA) has urged health ministers of the UK to take a strict and necessary action against the unnecessary closures of
pharmacy.
Concerned over the rising number of pharmacy closures, PDA has written an open letter to health secretary Steve Barclay; Robin Swann, health minister for Northern
Ireland; Eluned Morgan, minister of health and social services for Wales; and Humza Yousaf, the Scottish health secretary.
In its letter, PDA said: "The minister of health must now ensure the regulation of poor business behaviours and be prepared to take over rogue pharmacies, however
large their corporate owner may be. If patients' access to NHS services is to be protected from the consequences of avoidable full or part-day pharmacy closures."
The association believes it is only a matter of time before serious harm to patients' health will be caused by the decisions of mainly large chains of pharmacies to
close some of their branches for all or part of a day, instead of engaging an available pharmacist to cover their agreed opening hours.
"While a small number of unforeseen closures have always occurred from time to time in pharmacies for genuine reasons, the indiscriminate scale at which closures
have now become commonplace seems to have evolved over the last 20 months."